BioPharma Resources

Drug Trial Radar · NCT07165028

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 4,500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

4,500

Planned (sponsor's estimate)

Start

Oct 15, 2025

Primary completion

Aug 2030

Study completion Aug 2032

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Sep 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll about 4,500 adults and will run for approximately 224 weeks. Participants may have up to approximately 25 to 30 clinic visits throughout the study to monitor their health, complete study procedures, and assess liver function and disease progression. Once the study is complete, eligible participants may participate in an optional 2-year extension study, in which all participants will receive either retatrutide or tirzepatide, even if they received placebo in the main study.

Conditions

  • Metabolic Dysfunction-Associated Steatotic Liver Disease

Interventions

  • TirzepatideDrug

    Administered SC

  • RetatrutideDrug

    Administered SC

  • PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes (MALO)Time frame: Baseline up to Study Completion (about 224 weeks)

Locations

563 sites in 34 countries. Site status is shown where the registry gives one.

  • MFA Clinical Research

    Tuscaloosa, Alabama · Recruiting

  • The Institute for Liver Health II dba Arizona Clinical Trials - Chandler

    Chandler, Arizona · Recruiting

  • Spectrum Research Institute

    Gilbert, Arizona · Recruiting

  • The Institute for Liver Health II dba Arizona Liver Health - Peoria

    Peoria, Arizona · Recruiting

  • Epic Medical Research-Sun City

    Sun City, Arizona · Recruiting

  • The Institute for Liver Health II dba Arizona Clinical Trials - Tucson

    Tucson, Arizona · Recruiting

  • Del Sol Research Management, LLC

    Tucson, Arizona · Recruiting

  • Arkansas Gastroenterology - North Little Rock

    North Little Rock, Arkansas · Recruiting

  • San Fernando Valley Health Institute

    Canoga Park, California · Recruiting

  • Ark Clinical Research - Fountain Valley

    Fountain Valley, California · Recruiting

  • Fresno Clinical Research Center

    Fresno, California · Recruiting

  • UCSD - Altman Clinical and Translational Research Institute (ACTRI)

    La Jolla, California · Recruiting

  • Orange County Research Center

    Lake Forest, California · Recruiting

  • Om Research LLC

    Lancaster, California · Recruiting

  • Ark Clinical Research

    Long Beach, California · Recruiting

  • Los Angeles Institute for Metabolic Research

    Los Angeles, California · Recruiting

  • United Medical Doctors - Murrieta

    Murrieta, California · Recruiting

  • Knowledge Research Center

    Orange, California · Recruiting

  • California Liver Research Center

    Pasadena, California · Recruiting

  • Artemis Institute for Clinical Research

    Riverside, California · Recruiting

  • Medical Associates Research Group

    San Diego, California · Recruiting

  • Quest Clinical Research

    San Francisco, California · Recruiting

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • South Denver Gastroenterology

    Englewood, Colorado · Recruiting

  • Medical Research Center of Connecticut

    Hamden, Connecticut · Recruiting

  • K2 Medical Research WINTER GARDEN

    Clermont, Florida · Recruiting

  • K2 Medical Research - Daytona Beach

    Daytona Beach, Florida · Recruiting

  • Care Access - Delray Beach

    Delray Beach, Florida · Recruiting

  • AMR Clinical

    Doral, Florida · Recruiting

  • Southwest General Healthcare Center

    Fort Myers, Florida · Recruiting

  • University of Florida College of Medicine

    Gainesville, Florida · Recruiting

  • Encore Medical Research

    Hollywood, Florida · Recruiting

  • Nature Coast Clinical Research - Inverness

    Inverness, Florida · Recruiting

  • Encore Borland-Groover Clinical Research

    Jacksonville, Florida · Recruiting

  • Health Awareness

    Jupiter, Florida · Recruiting

  • K2 MEDICAL Research THE VILLAGES

    Lady Lake, Florida · Recruiting

  • Florida Research Institute

    Lakewood Rch, Florida · Recruiting

  • Tampa Bay Medical Research - Largo

    Largo, Florida · Recruiting

  • Evolution Clinical Trials

    Miami, Florida · Recruiting

  • Floridian Clinical Research, LLC

    Miami Lakes, Florida · Recruiting

Showing 40 of 563 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.